These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 21423118

  • 1. Efficacy of folinic acid in preventing oral mucositis in allogeneic hematopoietic stem cell transplant patients receiving MTX as prophylaxis for GVHD.
    Sugita J, Matsushita T, Kashiwazaki H, Kosugi M, Takahashi S, Wakasa K, Shiratori S, Ibata M, Shono Y, Shigematsu A, Obara M, Fujimoto K, Endo T, Nishio M, Kondo T, Hashino S, Tanaka J, Asaka M, Imamura M.
    Bone Marrow Transplant; 2012 Feb; 47(2):258-64. PubMed ID: 21423118
    [Abstract] [Full Text] [Related]

  • 2. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens.
    Cutler C, Li S, Kim HT, Laglenne P, Szeto KC, Hoffmeister L, Harrison MJ, Ho V, Alyea E, Lee SJ, Soiffer R, Sonis S, Antin JH.
    Biol Blood Marrow Transplant; 2005 May; 11(5):383-8. PubMed ID: 15846292
    [Abstract] [Full Text] [Related]

  • 3. Folinic acid administration following MTX as prophylaxis for GVHD in allogeneic HSCT centres in Australia and New Zealand.
    Bhurani D, Schifter M, Kerridge I.
    Bone Marrow Transplant; 2008 Oct; 42(8):547-50. PubMed ID: 18622418
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
    Rosenbeck LL, Kiel PJ, Kalsekar I, Vargo C, Baute J, Sullivan CK, Wood L, Abdelqader S, Schwartz J, Srivastava S, Abonour R, Robertson MJ, Nelson RP, Cornetta K, Fausel CA, Farag SS.
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):916-22. PubMed ID: 20932925
    [Abstract] [Full Text] [Related]

  • 7. Addition of low-dose folinic acid to a methotrexate/cyclosporin A regimen for prevention of acute graft-versus-host disease.
    Russell JA, Woodman RC, Poon MC, Jones AR, Ruether BA.
    Bone Marrow Transplant; 1994 Sep; 14(3):397-401. PubMed ID: 7994261
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Folinic acid supplementation in higher doses is associated with graft rejection in pediatric hematopoietic stem cell transplantation.
    Lindqvist H, Remberger M, Harila-Saari A, Winiarski J, Sundin M.
    Biol Blood Marrow Transplant; 2013 Feb; 19(2):325-8. PubMed ID: 23200704
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Etoposide induces more severe mucositis than CY when added to TBI as conditioning in allograft recipients receiving CsA and MTX.
    Hoyt R, Ritchie DS, Wirth A, Szer J, Grigg AP.
    Bone Marrow Transplant; 2010 Sep; 45(9):1457-62. PubMed ID: 20062098
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Folinic acid administration after MTX GVHD prophylaxis in pediatric allo-SCT.
    Hudspeth MP, Heath TS, Chiuzan C, Garrett-Mayer E, Nista E, Burton L, Ragucci D.
    Bone Marrow Transplant; 2013 Jan; 48(1):46-9. PubMed ID: 22609886
    [Abstract] [Full Text] [Related]

  • 14. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation.
    Pérez-Simón JA, Díez-Campelo M, Martino R, Brunet S, Urbano A, Caballero MD, de León A, Valcárcel D, Carreras E, del Cañizo MC, López-Fidalgo J, Sierra J, San Miguel JF.
    Br J Haematol; 2005 Aug; 130(3):394-403. PubMed ID: 16042689
    [Abstract] [Full Text] [Related]

  • 15. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP, Chen CS, Tai BC, Hwang WY, Tan LK, Ng HY, Linn YC, Koh MB, Goh YT, Tan B, Lim S, Lee YM, Tan KW, Liu TC, Ng HJ, Loh YS, Mow BM, Tan DC, Tan PH.
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Influence of post-methotrexate folinic acid rescue on regimen-related toxicity and graft-versus-host disease after allogeneic bone marrow transplantation.
    Nevill TJ, Tirgan MH, Deeg HJ, Klingemann HG, Reece DE, Shepherd JD, Barnett MJ, Phillips GL.
    Bone Marrow Transplant; 1992 May; 9(5):349-54. PubMed ID: 1617319
    [Abstract] [Full Text] [Related]

  • 18. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, Micozzi A, Fenu S, Laurenti L, Donato V, De Felice L, Arcese W.
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [Abstract] [Full Text] [Related]

  • 19. Prophylaxis of graft-versus-host disease with cyclosporine-prednisone is associated with increased risk of chronic graft-versus-host disease.
    Kumar S, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, Harmsen WS, Litzow MR.
    Bone Marrow Transplant; 2001 Jun; 27(11):1133-40. PubMed ID: 11551023
    [Abstract] [Full Text] [Related]

  • 20. Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: long-term outcomes.
    Uberti JP, Ayash L, Braun T, Reynolds C, Silver S, Ratanatharathorn V.
    Bone Marrow Transplant; 2004 Sep; 34(5):425-31. PubMed ID: 15273705
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.